OCS Oculis Holding AG IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1953530 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 57.09M | 52.08M |
| SG&A expense | 25.79M | 21.81M |
| Operating income | -81.67M | -73.20M |
| Interest expense | 833,000 | 639,000 |
| Pretax income | -99.14M | -85.94M |
| Income tax | -186,000 | -160,000 |
| Net income | -98.96M | -85.78M |
| EPS (basic) | -1.89 | -2.12 |
| EPS (diluted) | -1.89 | -2.12 |
| Weighted avg. shares (diluted) | 52.24M | 40.41M |
| Balance sheet | ||
| Cash & equivalents | 81.33M | 27.71M |
| Current assets | 218.89M | 104.90M |
| PP&E, netmay include right-of-use assets (IFRS) | 534,000 | 385,000 |
| Intangibles | 13.29M | 13.29M |
| Total assets | 235.96M | 120.35M |
| Current liabilities | 36.75M | 44.23M |
| Total liabilities | 39.89M | 46.97M |
| Shareholders' equity | 196.07M | 73.38M |
| Cash flow statement | ||
| Operating cash flow | -66.30M | -48.92M |
| Capital expenditure | 301,000 | 230,000 |
| Free cash flow | -66.61M | -49.15M |
| Investing cash flow | -60.93M | -16.08M |
| Financing cash flow | 186.92M | 53.98M |
| Stock-based compensation | 16.04M | 9.78M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.